Roland Veltkamp received his clinical training as a stroke neurologist in Heidelberg, Germany, and at Wake Forest University School of Medicine, USA. His research interests encompass emergency therapy of ischemic and hemorrhagic stroke and stroke prevention in atrial fibrillation. His research has led to new methods of Afib detection on the stroke unit and to the improvement of acute stroke management in patients on anticoagulants. His translational stroke research group investigates the role of the immune system after stroke. In a landmark study, his group has described a major protective role of regulatory T cells in experimental stroke. Recent findings in his laboratory have led to a phase II clinical stroke trial testing the effect of the leukocyte adhesion blocker natalizumab in stroke.
Currently, Prof. Veltkamp serves as a member of the Board of Directors of the European Stroke Organisation and is an international delegate of the program committee of the AHA International Stroke Conference.
et al., 2024, Burden of intracerebral haemorrhage in Europe: forecasting incidence and mortality between 2019 and 2050., Lancet Reg Health Eur, Vol:38
et al., 2023, Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials., Lancet Neurol, Vol:22, Pages:1140-1149
et al., 2023, The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial, Lancet Neurology, Vol:22, ISSN:1474-4422, Pages:787-799
et al., 2023, Progression of initially unilateral Moyamoya angiopathy in Caucasian Europeans, Journal of Neurology, Vol:270, ISSN:0340-5354, Pages:4415-4422
et al., 2023, Penumbral Rescue by normobaric O?=?O administration in patients with ischemic stroke and target mismatch proFile (PROOF): Study protocol of a phase IIb trial, International Journal of Stroke, ISSN:1747-4930